CELIA
OREJA GUEVARA
Profesora asociada de Ciencias de la Salud
Hospital Vall d'Hebron
Barcelona, EspañaPublicacions en col·laboració amb investigadors/es de Hospital Vall d'Hebron (42)
2024
-
Clinical characteristics and impact on patient-reported outcomes and quality of life of people with ambulatory secondary progressive multiple sclerosis: Discover study
Multiple Sclerosis and Related Disorders, Vol. 90
-
Consensus statement of the Spanish Society of Neurology on the treatment of multiple sclerosis and holistic patient management in 2023
Neurologia, Vol. 39, Núm. 2, pp. 196-208
-
Defining a standard set of health outcomes for patients with relapsing-remitting multiple sclerosis
Multiple Sclerosis and Related Disorders, Vol. 84
2023
-
European Committee for Treatment and Research in Multiple Sclerosis and European Academy of Neurology consensus on vaccination in people with multiple sclerosis: Improving immunization strategies in the era of highly active immunotherapeutic drugs
European Journal of Neurology, Vol. 30, Núm. 8, pp. 2144-2176
-
XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (I)
Revista de neurologia, Vol. 77, Núm. 1, pp. 19-30
-
XV Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2022 (II)
Revista de neurologia, Vol. 77, Núm. 2, pp. 47-60
2022
-
Autoimmunity and long-term safety and efficacy of alemtuzumab for multiple sclerosis: Benefit/risk following review of trial and post-marketing data
Multiple Sclerosis Journal, Vol. 28, Núm. 5, pp. 842-846
-
Consensus on early detection of disease progression in patients with multiple sclerosis
Frontiers in Neurology, Vol. 13
-
Consensus statement on the use of alemtuzumab in daily clinical practice in Spain
Neurologia, Vol. 37, Núm. 8, pp. 615-630
-
The risk of infections for multiple sclerosis and neuromyelitis optica spectrum disorder disease-modifying treatments: Eighth European Committee for Treatment and Research in Multiple Sclerosis Focused Workshop Review. April 2021
Multiple sclerosis (Houndmills, Basingstoke, England), Vol. 28, Núm. 9, pp. 1424-1456
2021
-
Four-year safety and effectiveness data from patients with multiple sclerosis treated with fingolimod: The Spanish GILENYA registry
PLoS ONE, Vol. 16, Núm. 10 October
-
SARS-CoV-2 Infection in Multiple Sclerosis: Results of the Spanish Neurology Society Registry
Neurology(R) neuroimmunology & neuroinflammation, Vol. 8, Núm. 5
-
XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (I)
Revista de neurologia, Vol. 72, Núm. 11, pp. 397-406
-
XIII Reunión Post-ECTRIMS: revisión de las novedades presentadas en el Congreso ECTRIMS 2020 (II)
Revista de neurologia, Vol. 72, Núm. 12, pp. 433-442
2019
-
Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study
Multiple Sclerosis Journal, Vol. 25, Núm. 3, pp. 352-360
-
Review of the novelties presented at the 2018 ECTRIMS congress: 11th post-ECTRIMS meeting (II)
Revista de Neurologia, Vol. 68, Núm. 11, pp. 468-479
-
Review of the novelties presented at the 2018 ectrims congress: 11th post-ectrims meeting (I)
Revista de Neurologia, Vol. 68, Núm. 10, pp. 431-441
2017
-
Revisión de las novedades del XXXII Congreso ECTRIMS 2016, presentadas en la IX Reunión Post-ECTRIMS (II)
Revista de Neurologia, Vol. 65, Núm. 2, pp. 75-84
-
Revisión de las novedades del XXXII congreso ectrims 2016, presentadas en la ix reunión post-ectrims (I)
Revista de Neurologia, Vol. 65, Núm. 1, pp. 31-40
2016
-
Respuesta al tratamiento con interferón beta en pacientes con esclerosis múltiple. Validación del Rio Score
Revista de Neurologia, Vol. 63, Núm. 4, pp. 145-150